Stockscreener 앱 받기
6.00
18.81%
0.95
시간 외 거래:
6.07
0.07
+1.17%
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
FHTXFoghorn Therapeutics Inc Options - Finviz
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - Investing News Network
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewswire Inc.
Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings - Barchart.com
Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX) - TradingView
Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
FHTX Forecast — Price Target — Prediction for 2027 - TradingView
Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike - Stock Titan
Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares - Stock Titan
Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant - Stock Titan
Director Michael Mendelsohn gets 28,000 Foghorn (FHTX) stock options at $4.08 - Stock Titan
Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options - Stock Titan
Director Douglas G. Cole receives 28,000 Foghorn (NASDAQ: FHTX) stock options - Stock Titan
Foghorn Therapeutics Stockholders Approve Directors and Governance Matters - The Globe and Mail
Shareholders at Foghorn Therapeutics (NASDAQ: FHTX) approve pay and auditor - Stock Titan
Foghorn Therapeutics Inc. (FHTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Foghorn Therapeutics Inc. (FHTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Foghorn Therapeutics Inc. (FHTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics Inc. (FHTX) Institutional Confidence - TradingKey
Foghorn Therapeutics Inc. (FHTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Foghorn Therapeutics Inc. (FHTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Foghorn Therapeutics Inc. (FHTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Foghorn Therapeutics Inc. (FHTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Foghorn Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Investing News Network
Biotech Foghorn CEO to speak at Goldman Sachs global healthcare event - Stock Titan
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Jade Biosciences (JBIO) - The Globe and Mail
Foghorn Therapeutics to Present at Three Investor Conferences in May - geneonline.com
Foghorn Therapeutics (FHTX) Rises 1.44% as Biotech Stock Tests Key Resistance at $4.43MESA MA - newsline.com
Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX) - Stock Titan
EDGAR Filing Documents for 0001628280-25-014475 - SEC.gov
[SCHEDULE 13G/A] Foghorn Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Foghorn Therapeutics discloses new EP300 degradation inducers - BioWorld News
Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments - Traders Union
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Investing News Network
Biotech Foghorn lines up three May oncology investor events - Stock Titan
Foghorn Therapeutics Inc. (FHTX) may report negative earnings: Know the trend ahead of Q1 release - MSN
Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report - simplywall.st
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
1.17%
2.48%
자본화:
|
볼륨(24시간):